Premium
Chloramphenicol serum concentration falls during chloramphenicol succinate dosing
Author(s) -
Nahata Milap C,
Powell Dwight A
Publication year - 1983
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1983.38
Subject(s) - chloramphenicol , chemistry , pharmacokinetics , steady state (chemistry) , dosing , chromatography , medicine , endocrinology , antibiotics , biochemistry
Chloramphenicol succinate and chloramphenicol kinetics were examined on two occasions at steady state, separated by 2 to 17 days, in 10 pediatric patients on the same intravenous dose of chloramphenicol succinate. The steady‐state peak serum concentration of chloramphenicol succinate fell from an average of 77.1 µg/ml during the first study to 42.2 µg/ml during the second. The steady‐state peak serum concentration of chloramphenicol also decreased from an average of 27.8 µg/ml to 24.9 µg/ml. There was a marked decrease in the steady‐state trough serum concentration of chloramphenicol, which averaged 8.4 µg/ml during the first and 5.3 µg/ml at the time of the second study. Mean area under the serum concentration–time curve (AUC) of chloramphenicol succinate decreased from 59.7 µg · hr/ml to 24.0 µg · hr/ml. The AUC of chloramphenicol averaged 105.7 µg · hr/ml at the time of the first and decreased to 79.5 µg · hr/ml during the second study. Mean percent decrease in the AUC of chloramphenicol was about 28% and occurred most substantially in patients with high AUCs during the first study. Mean elimination chloramphenicol half‐life was 3.0 hr during the first study and fell to 2.3 hr at the time of the second study. Our data indicate that chloramphenicol serum concentration should be monitored frequently, especially in patients not responsive to a set dose. Clinical Pharmacology and Therapeutics (1983) 33, 308–313; doi: 10.1038/clpt.1983.38